11:28 AM EST - Bausch Health Companies Inc. : And Glenmark Specialty S.A., a subsidiary of Glenmark Pharmaceuticals Ltd. (Glenmark) announced that RYALTRIS® (olopatadine hydrochloride and mometasone furoate nasal spray) has been approved by Health Canada for the symptomatic treatment of moderate to severe seasonal allergic rhinitis (SAR) and associated ocular symptoms in adults, adolescents, and children aged six years and older. Bausch Health Companies Inc.
shares T.BHC are trading down $0.20 at $9.43.
